Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

OVID

Ovid Therapeutics (OVID)

Ovid Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OVID
DateTimeSourceHeadlineSymbolCompany
30/01/202501:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
17/12/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
17/12/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
03/12/202400:00GlobeNewswire Inc.Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual MeetingNASDAQ:OVIDOvid Therapeutics Inc
13/11/202400:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
13/11/202400:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
13/11/202400:00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
31/10/202423:00GlobeNewswire Inc.Ovid Therapeutics to Host Investor EventNASDAQ:OVIDOvid Therapeutics Inc
26/09/202422:00GlobeNewswire Inc.Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with VigabatrinNASDAQ:OVIDOvid Therapeutics Inc
12/09/202407:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
12/09/202407:36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OVIDOvid Therapeutics Inc
12/09/202406:57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
11/09/202422:00GlobeNewswire Inc.Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthNASDAQ:OVIDOvid Therapeutics Inc
04/09/202422:00GlobeNewswire Inc.Ovid Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:OVIDOvid Therapeutics Inc
13/08/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
13/08/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
13/08/202422:00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
08/08/202422:00GlobeNewswire Inc.Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerNASDAQ:OVIDOvid Therapeutics Inc
03/08/202407:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
30/07/202422:00GlobeNewswire Inc.Ovid Therapeutics to Present at Upcoming August Investor ConferencesNASDAQ:OVIDOvid Therapeutics Inc
23/07/202422:00GlobeNewswire Inc.Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsNASDAQ:OVIDOvid Therapeutics Inc
10/07/202422:00GlobeNewswire Inc.eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant SeizuresNASDAQ:OVIDOvid Therapeutics Inc
01/07/202422:00GlobeNewswire Inc.Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous MalformationsNASDAQ:OVIDOvid Therapeutics Inc
17/06/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
17/06/202420:55GlobeNewswire Inc.Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for SoticlestatNASDAQ:OVIDOvid Therapeutics Inc
08/06/202406:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
15/05/202407:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OVIDOvid Therapeutics Inc
14/05/202422:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OVIDOvid Therapeutics Inc
14/05/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OVIDOvid Therapeutics Inc
14/05/202422:00GlobeNewswire Inc.Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsNASDAQ:OVIDOvid Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OVID

Your Recent History

Delayed Upgrade Clock